|Medical equipment data|
|Export to||Open Know How Manifest|
|Part of||Global Health Medical Device Compendium|
|Type||Medical equipment, Project|
|SDGs Sustainable Development Goals||SDG03 Good health and well-being|
|License||CC BY-SA 3.0|
|Translate to||Français, Español, Kiswahili, 中文, العربية, Русский, more|
|Export to||PDF, LaTeX, EPUB, ODT|
|Cite as Evashiu (2021). "BD SoloShot LX". Appropedia. Retrieved 2021-10-18.|
Problem being addressed[edit | edit source]
Systematic immunization of newborn children plays a vital role in reducing the disease burden around the world, and syringes and needles are obviously of utmost importance in performing immunizations. However, the misuse of these devices contributes to the transmission of deadly blood-borne diseases such as Hepatitis B and HIV/AIDS. Each year, more than 12 billion injections are administered worldwide; last year in developing countries an estimated 50 percent of injections were deemed to be unsafe. When syringes and needles are reused on multiple patients, disease can easily be transmitted from one patient to another.
Detailed description of the solution[edit | edit source]
The BD SoloShot LX Syringe is designed to prevent the syringe and the needle from being reused. After an injection is given to a patient, the plunger automatically locks and the syringe and needle cannot be reused.
Designed by[edit | edit source]
- Designed by: Program for Appropriate Technologies in Health (PATH)
- Manufacturing: This technology has been licensed and is now manufactured and marketed by BD (Becton, Dickinson & Company) in facilities around the world.
- Headquarters: BD Medical, 1 Becton Drive, MC204, Franklin Lakes, NJ 07417
Testing/Implementation[edit | edit source]
BD conducted a clinical trial in Columbia in 2001 and the device is currently distributed in over 50 countries.
Funding Source[edit | edit source]
This project is privately funded by BD Medical. Funding has also come from the United States Agency for International Development (USAID) under PATH's HealthTech program.
References[edit | edit source]
Peer-reviewed publication[edit | edit source]
Griffiths UK, Santoas AC, Nundy N et al. (2010.) Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: comparative analysis from Brazil, India, and South Africa. Vaccine 29(5):969-975. Abstract available here.
Nelson CM, Sutanto A and Suradana IGP. (1999.) Use of SoloShot autodestruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia. Bulletin of the WHO 77(1):29-33. PDF available here.
Other internally generated reports[edit | edit source]
BD (2011). The BD™ SoloShot® Syringe BCG Auto-Disable Syringe. PDF available here.
PATH (2011).Technology solutions for global health. PDF available here.
IP and copyright[edit | edit source]
Publication number: US 2010/0174236 A1 Filing date: Nov 25, 2009
Approval by regulatory bodies or standards boards[edit | edit source]
CE-Mark (CE-0086) FDA Approval 10/28/2004